Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NexHand Inc.

Precisely quantifying SUI severity and sling tension

This article was originally published in Start Up

Executive Summary

NexHand Inc. has developed proprietary, sensor-based "smart surgical glove" technology designed to enable physicians to assess the severity of stress urinary incontinence. Its technology has been developed into two disposable products: the first is a noninvasive diagnostic tool for assessing the severity of SUI in the clinical setting, the UroGlove, and the second is a probe-based sensor for determining proper tensioning of urethral slings during surgery.

You may also be interested in...



Medtech Start-Ups Innovate In Urinary Incontinence

Angel- and venture-backed medtech start-ups are working to fill the tremendous unmet need for alternative device options for treating (not just managing) female urinary incontinence a condition that has a significant impact on quality of life for millions of women. In this issue we profile Floelle, InControl Medical, NexHand, and Solace Therapeutics.

JB Chemicals Acquires Several Sanzyme Brands

JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.

German HTA Negative On Benefits Of First Ever Peanut Allergy Treatment

The decision by IQWiG could have an impact on how Palforzia is priced if the findings are upheld.

Topics

UsernamePublicRestriction

Register

MT037769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel